De-Escalated Neoadjuvant Chemoimmunotherapy Shows Promise in Early TNBC

[ad_1]

(MedPage Today) — Use of nivolumab (Opdivo) before chemotherapy was not associated with improved pathologic complete response (pCR) rates among patients with early triple-negative breast cancer (TNBC), but a 12-week non-anthracycline regimen in…

[ad_2]

Source link : https://www.medpagetoday.com/hematologyoncology/breastcancer/114604

Author :

Publish date : 2025-03-11 20:39:00

Copyright for syndicated content belongs to the linked Source.